![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Heritage Mining Ltd | CSE:HML | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 9.09% | 0.06 | 0.06 | 0.07 | 0.06 | 0.055 | 0.055 | 480,000 | 20:12:56 |
RNS Number:5502S Henderson Morley PLC 27 November 2003 Henderson Morley PLC 27 November 2003 Start of Phase II studies Following Croma Pharma's successful completion of the initial (Phase I) work on the ocular application of ICVT, the Directors of Henderson Morley are pleased to announce the start of patient recruitment in an International, multi-centre, randomised, double-blinded placebo controlled phase ll clinical trial. The study will examine the safety and efficacy of Ionic Contra Viral Therapy (ICVT), the Company's lead technology, when used to treat Adenovirus Keratoconjunctivitis. The study, funded by Croma, will recruit 140 patients and be carried out in six centres in Austria and Slovakia. Patients will be monitored by slit lamp microscope at several stages of the infection, and only patients who have a positive diagnosis of adenovirus infection (confirmed using molecular biological techniques) will be included in the study. The treatment will be in the form of aqueous drops applied during the course of the infection and it is anticipated that patients will not require treatment for longer than 21 days. Adenovirus Keratoconjunctivitis Adenoviral keratoconjunctivitis is a highly contagious disease that occurs worldwide sporadically and epidemically. Although not permanently blinding, adenoviral ocular infections remain the most common external ocular viral infection worldwide. The natural course of the acute phase of adenoviral keratoconjunctivitis has a wide spectrum of duration and intensity of local symptoms. After an incubation period of 2 to 14 days, symptoms usually begin in one eye, and the other eye becomes symptomatic after 2 to 4 more days. Typical symptoms include conjunctival hyperemia and chemosis, swelling of the conjunctival plica, and intense tearing. Conjunctival pseudomembranes occur in some cases. The corneal involvement sets the adenoviral keratoconjunctivitis apart from other forms of viral conjunctivitis. During the course of the infection corneal subepithelial opacities frequently develop. These nummular opacities or infiltrates can impair visual function and can persist for months to years, and therefore make treatment of this debilitating condition desirable. Currently, no specific antiviral therapy is available to shorten the course of the infection, to improve the distressful clinical symptoms, to stop viral replication, or to avoid the development of corneal opacities. Ionic Contra Viral Therapy ICVT is an innovative compound for treating virus infections. It exploits the little known finding, that many of the biological processes involved with virus DNA synthesis are sensitive to local potassium ion concentrations. ICVT uses a proprietary combination of two established drugs currently used in cardiovascular medicine that have no prior use as anti-virals. The component drugs used in ICVT cause depletion of intracellular potassium and inhibit the replication of DNA viruses, while normal host cell metabolism and function is only minimally affected. By combining two compounds that act on ion transport in different ways, the antiviral effect is enhanced. This combination therefore offers the prospect of preventing viral replication with little or no adverse effects. The anti-viral effects of the two drugs in ICVT are synergistic. The effects of ICVT on host cell metabolism have been measured in a variety of cell lines and the rate of cell metabolism is unaffected by prolonged incubation with ICVT. Pilot human studies have not demonstrated any local or systemic toxicity when used at anti-virally effective doses. Additionally, the component drugs used in ICVT have a long history of being widely co-prescribed in the treatment of cardiovascular disease. As such, ICVT offers potential in the treatment of a range of viral infections for which current therapy is inadequate, such as adenovirus. The directors believe that no other antiviral treatments are under clinical development for Adenovirus Keratoconjunctivitis, and if further studies prove successful ICVT could address a sizeable market of unmet medical need. ICVT is currently being investigated as a treatment for several other DNA virus infections, and clinical developments will be reported in due course. Timeline of Phase II studies Croma anticipates providing early verbal results in February 2004, and formal written results in April 2004. Andrew Knight, Chairman of Henderson Morley, commented: "This is a very important study for both Croma and Henderson Morley. Not only will the resultant data be used to take the technology on to a Phase III trial but it will be used to secure out licenses in other territories, not covered by the original Croma agreement." ---Ends--- Copies of this announcement will be available free of charge to the public at the Company's registered office at Metropolitan House, 2 Salisbury Road, Moseley, Birmingham, B13 8JS and at the offices of Brewin Dolphin Securities Ltd, 34 Lisbon Street, Leeds LS1 4LX for 14 days. Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600 Andrew Knight, Chairman BREWIN DOLPHIN SECURITIES LTD Tel: 0113 241 0126 Neil Baldwin BISHOPSGATE COMMUNICATIONS Tel: 020 7430 1600 Maxine Barnes Mobile 07860 489571 This information is provided by RNS The company news service from the London Stock Exchange END MSCDQLFLXFBLFBK
1 Year Heritage Mining Chart |
1 Month Heritage Mining Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions